<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04541576</url>
  </required_header>
  <id_info>
    <org_study_id>CVO-P3-20-01-F</org_study_id>
    <nct_id>NCT04541576</nct_id>
  </id_info>
  <brief_title>The Merit WRAPSODY Central Feasibility Study</brief_title>
  <acronym>WAVE Central</acronym>
  <official_title>Prospective, Non-Randomized, Controlled, Multicenter Feasibility Study of the Merit WRAPSODY™ Endovascular Stent Graft for Treatment of Central Venous Outflow Circuit Stenosis or Occlusion in Hemodialysis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merit Medical Systems, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ClinLogix. LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Merit Medical Systems, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to demonstrate the safety and efficacy of the Merit WRAPSODY&#xD;
      Endovascular Stent Graft for treatment of stenosis or occlusion within the dialysis access&#xD;
      outflow circuit in the thoracic central veins&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    FDA Approval&#xD;
  </why_stopped>
  <start_date type="Anticipated">March 2021</start_date>
  <completion_date type="Anticipated">February 2024</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects without any localized or systemic safety events (Primary Safety Endpoint</measure>
    <time_frame>30 days</time_frame>
    <description>Proportion of subjects without any localized or systemic safety events through 30 days post-index procedure that affect the access or venous outflow circuit and resulted in intervention, hospitalization, or death.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of subjects with Target Lesion Primary Patency (TLPP) (Primary Effectiveness Endpoint)</measure>
    <time_frame>6 months</time_frame>
    <description>Proportion of subjects with Target Lesion Primary Patency (TLPP) at 6 Months. TLPP is defined as freedom from clinically-driven target lesion revascularization (CD-TLR) or target lesion thrombosis measured through 6 months post-procedure, which is the time interval of uninterrupted patency after study procedure to the next intervention performed on the target lesion or uncorrectable target lesion occlusion.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with Target Lesion Primary Patency</measure>
    <time_frame>12 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with Assisted Target Lesion Primary Patency (aTLPP)</measure>
    <time_frame>6, 12 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with Access Circuit Primary Patency (ACPP)</measure>
    <time_frame>6, 12 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with Post-Procedure Secondary Patency</measure>
    <time_frame>6, 12 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of procedure- and device-related adverse events involving the access circuit</measure>
    <time_frame>Index procedure, 30 days, and months 6, 12 and 24.</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Venous Stenosis</condition>
  <condition>Venous Occlusion</condition>
  <arm_group>
    <arm_group_label>WRAPSODY Stent Graft</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects will receive treatment via WRAPSODY Stent Graft Placement.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Merit WRAPSODY Endovascular Stent Graft</intervention_name>
    <description>Target lesion treated with stent graft placement</description>
    <arm_group_label>WRAPSODY Stent Graft</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject provides written informed consent&#xD;
&#xD;
          -  Subject is male or female, with an age ≥ 18 years at date of enrollment.&#xD;
&#xD;
          -  Subject is willing to undergo all follow-up assessments.&#xD;
&#xD;
          -  Subject has a life expectancy ≥ 12 months.&#xD;
&#xD;
          -  Subject is undergoing chronic hemodialysis.&#xD;
&#xD;
          -  Subject has either a mature AVF or AVG in the arm.&#xD;
&#xD;
          -  Target lesion(s) involves a non-stented restenotic lesion.&#xD;
&#xD;
          -  Target lesion has ≥50% stenosis.&#xD;
&#xD;
          -  Target lesion(s) reference vessel diameter is between 5.0 mm and 14.0 mm&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject is unable or is unwilling to comply with the procedural requirements of the&#xD;
             study protocol.&#xD;
&#xD;
          -  Subject has a comorbidity that in the investigator's opinion would limit life&#xD;
             expectancy to less than 12 months.&#xD;
&#xD;
          -  Subject has a known or suspected infection of the hemodialysis access site, systemic&#xD;
             infection and/or septicemia.&#xD;
&#xD;
          -  Subject has a stroke diagnosis within 3 months prior to enrollment.&#xD;
&#xD;
          -  Subject has a history of unstable angina or myocardial infarction within 60 days prior&#xD;
             to enrollment.&#xD;
&#xD;
          -  Subject is pregnant, breastfeeding, or intending to become pregnant within the next&#xD;
             year.&#xD;
&#xD;
          -  Target lesion is located within a stent / stent graft.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>September 1, 2020</study_first_submitted>
  <study_first_submitted_qc>September 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 9, 2020</study_first_posted>
  <last_update_submitted>April 16, 2021</last_update_submitted>
  <last_update_submitted_qc>April 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constriction, Pathologic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

